STOCK TITAN

Perceptive fund discloses 9.99% Palisade Bio (PALI) ownership stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Perceptive Advisors and affiliates reported a significant ownership position in Palisade Bio, Inc. The filing shows beneficial ownership of 15,200,117 shares of common stock, representing 9.99% of the class, including shares underlying pre-funded warrants.

The Master Fund directly holds 12,050,000 common shares and pre-funded warrants for 5,185,714 additional shares at an exercise price of $0.0001 per share, subject to a 9.99% beneficial ownership cap. Ownership percentages are based on 149,003,210 shares outstanding as of November 5, 2025. The reporting persons certify the holdings are not for the purpose of changing or influencing control of Palisade Bio.

Positive

  • None.

Negative

  • None.

Insights

Perceptive discloses a capped 9.99% economic stake in Palisade Bio.

Perceptive Advisors LLC, its Master Fund, and Joseph Edelman jointly report beneficial ownership of 15,200,117 Palisade Bio common shares, equal to 9.99% of the company. This includes common shares plus pre-funded warrants, giving them a sizable but non-controlling position.

The Master Fund holds 12,050,000 common shares and pre-funded warrants for 5,185,714 shares at an exercise price of $0.0001 per share. A contractual Beneficial Ownership Limitation prevents exercising warrants above 9.99% of outstanding shares, effectively capping voting power.

The ownership percentage is calculated using 149,003,210 shares outstanding as of November 5, 2025. The reporting group certifies that the securities are not held to change or influence control, indicating a financial-investor posture rather than an activist or strategic control agenda based on this disclosure alone.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:02/17/2026
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:02/17/2026
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:02/17/2026

FAQ

What ownership stake in Palisade Bio (PALI) does Perceptive report?

Perceptive Advisors, its Master Fund, and Joseph Edelman report beneficial ownership of 15,200,117 Palisade Bio common shares, representing 9.99% of the outstanding class. This figure includes common stock plus currently exercisable pre-funded warrants, based on 149,003,210 shares outstanding as of November 5, 2025.

How many Palisade Bio shares does Perceptive’s Master Fund directly hold?

Perceptive Life Sciences Master Fund, Ltd. directly holds 12,050,000 shares of Palisade Bio common stock. It also holds pre-funded warrants that are immediately exercisable for additional shares, subject to a contractual 9.99% beneficial ownership limitation that restricts further exercises above that threshold.

What are the terms of Perceptive’s pre-funded warrants in Palisade Bio (PALI)?

The Master Fund holds pre-funded warrants for 5,185,714 Palisade Bio shares at an exercise price of $0.0001 per share. A 9.99% Beneficial Ownership Limitation caps how many warrants can be exercised, limiting aggregate beneficial ownership relative to outstanding common shares.

How is the 9.99% ownership percentage in Palisade Bio calculated?

The 9.99% figure is based on 149,003,210 Palisade Bio common shares outstanding as of November 5, 2025. It combines 12,050,000 common shares held by the Master Fund with a portion of its pre-funded warrants that are exercisable without breaching the 9.99% ownership cap.

Does Perceptive intend to influence control of Palisade Bio (PALI)?

The reporting persons certify that the securities were not acquired and are not held to change or influence control of Palisade Bio. They also state the holdings are not in connection with any transaction aimed at control, other than activities tied to a specific nomination rule reference.

Who are the reporting persons in this Palisade Bio Schedule 13G/A?

The filing lists three reporting persons: Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. All share voting and dispositive power over 15,200,117 Palisade Bio shares, with no sole voting or dispositive authority reported for any of them.
Palisade Bio Inc

NASDAQ:PALI

PALI Rankings

PALI Latest News

PALI Latest SEC Filings

PALI Stock Data

258.12M
6.13M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
CARLSBAD